Palm Multidiagnostic of Mycoplasma pneumoniae, Chlamydia pneumoniae, Haemophilus influenzae, and Streptococcus pneumoniae Using One-Tube CRISPR/Cas12a
Related Experiment Video
Updated: May 13, 2026

ELIME Enzyme Linked Immuno Magnetic Electrochemical Method for Mycotoxin Detection
Published on: October 23, 2009
Xingchi Kan1, Yue Wu1, Xiyue Zhang2
1Zhejiang Lab Hangzhou 311121China.
Abstract:
The recent high incidence of Mycoplasma pneumoniae (Mp) infections has raised widespread public health concerns. Therefore, rapid and accurate diagnosis of respiratory pathogenic microbial infections is of paramount importance to provide clinicians with accurate diagnostic insights and guide clinical medication. In response to this urgent need, we developed a one-tube Palm CRISPR/Cas12a Diagnostic (PaCD) method. This method facilitates the rapid detection of Mp infections, as well as three other prevalent respiratory pathogens, Chlamydia pneumoniae (Cp), Haemophilus influenzae (Hi), and Streptococcus pneumoniae (SP). In addition, 3D printing was employed to fabricate a compact detection device that includes a temperature control module set at 39°C and a blue light irradiation module, significantly enhancing the feasibility of point-of-care testing. The PaCD diagnostic process takes only 30 min with a detection limit of 50 copies/test, making it suitable for analysis of sputum and throat swab samples. PaCD demonstrated 100% concordance (72/72) with next-generation sequencing and exhibited high concordance with computed tomography test results. These findings demonstrate the clinical feasibility of PaCD for the rapid and accurate diagnosis of infections caused by four prevalent respiratory pathogens, offering theoretical insights into the versatile application of point-of-care tests for the detection of other respiratory pathogens in various clinical scenarios.
Insights
A new diagnostic method, Palm CRISPR/Cas12a Diagnostic (PaCD), rapidly detects four common respiratory pathogens, including Mycoplasma pneumoniae. This point-of-care test offers accurate results in 30 minutes, aiding clinical decisions.
Area of Science:
- Molecular Biology
- Infectious Diseases
- Biotechnology
Background:
- Rising incidence of Mycoplasma pneumoniae (Mp) infections necessitates rapid diagnostic tools.
- Accurate detection of respiratory pathogens is crucial for effective clinical management.
- Existing diagnostic methods may lack speed or point-of-care accessibility.
Purpose of the Study:
- To develop a rapid, accurate, and point-of-care diagnostic method for Mycoplasma pneumoniae and other key respiratory pathogens.
- To evaluate the performance of the developed diagnostic method using clinical samples.
- To assess the potential of 3D printing for creating portable diagnostic devices.
Main Methods:
- Development of a one-tube Palm CRISPR/Cas12a Diagnostic (PaCD) assay.
- Utilizing 3D printing to create a compact, portable detection device with temperature control and blue light irradiation.
- Testing PaCD with sputum and throat swab samples, comparing results with next-generation sequencing and CT scans.
Main Results:
- PaCD achieved a detection limit of 50 copies/test and provided results within 30 minutes.
- The method successfully detected Mycoplasma pneumoniae, Chlamydia pneumoniae, Haemophilus influenzae, and Streptococcus pneumoniae.
- PaCD showed 100% concordance with next-generation sequencing and high concordance with CT scan results.
Conclusions:
- The PaCD method offers a rapid and accurate point-of-care solution for diagnosing infections caused by four prevalent respiratory pathogens.
- The integration of 3D printing enhances the portability and feasibility of the diagnostic device.
- PaCD holds promise for versatile applications in detecting various respiratory pathogens in diverse clinical settings.
Related Concept Videos
CRISPR
CRISPR and crRNAs
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
The Antiviral System of Bacteria and Archaea: CRISPR
CRISPR/Cas9 Genome Editing
Atypical Pneumonia

